Disclosed herein are 1-cyclopropyl substituted 8-[6-amino-3-pyridyl]xanthines of the given general formula, processes for their preparation, compositions comprising said compounds and uses thereof. Said compounds are useful as selective antagonists of A2B adenosine receptors (ARs) and as such are useful in the treatment allergy, allergic diseases, an autoimmune disease, diarrheal disease, insulin resistance, diabetes, cancer, an ischemia/reprefusion injury, diabetic retinopathy or hyperbaric oxygen-induced retinopathy. Examples of particularly preferred compounds include: 1-Cyclopropyl-3-propyl-8-[6-(N-[6-(trifluoromethyl)nicotinoyl]-N-methylamino)-3-pyridyl]xanthine； 1-CyclopropyI-3-propyl-8-[6-(N-[6-(trifluoromethyl)nicotinoyI]-N-propylamino)-3-pyridyl]xanthine； 1-Cyclopropyl-3-propyl-8-[6-(N-[6-(trifluoromethyl)nicotinoyl]-N-(2-methoxyethyl)amino)-3-pyridyl]xanthirie； 1-Cyclopropyl-3-propyl-8-[6-(N-[6-fluoronicotinoyl]-N-[cyclopropylmethyl]amino )-3-pyridyl]xanthine； 1-Cyclopropyl-3-propyl-8-[6-(N-[6-(trifluoromethyl)nicotinoyl]-N-(2-[piperidin-1-yl]ethyl)amino)-3-pyridyl]xanthine； 1-Cyclopropyl-3-propyl-8-[6-(3-[trifluoro-m-tolyl)-1-(2,3-dihydroxypropyl]ureido)-3-pyridyl]xanthine.
